IL21R and neoplasm: T cell receptor-engineered T cells (TCR-T) modified with IL-21 receptors demonstrated enhanced proliferation upon activation and superior anti-tumor function both in vitro and in vivo compared to conventional TCR-T against hepatocellular carcinoma [32].